These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 122607)

  • 1. Positive correlation of serum uridine diphosphate-galactosyltransferase levels with breast carcinoma.
    Paone JF; Waalkes TP; Baker RR; Shaper JH
    Surg Forum; 1978; 29():158-60. PubMed ID: 122607
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum UDP-galactosyl transferase as a potential biomarker for breast carcinoma.
    Paone JF; Waalkes TP; Baker RR; Shaper JH
    J Surg Oncol; 1980; 15(1):59-66. PubMed ID: 6775160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple serum galactosyltransferase assay method suitable for routine use.
    Sichel F; Malas JP; Gauduchon P; Aubert M; Bar E; Le Talaër JY
    Clin Chim Acta; 1990 Apr; 188(1):49-58. PubMed ID: 2112065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzymatic synthesis of neolactotetraosylceramide by the N-acetyllactosamine synthase of human serum.
    Zieleński J; Kościelak J
    Eur J Biochem; 1982 Jul; 125(2):323-9. PubMed ID: 6811267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galactosyltransferase associated with tumor in patients with ovarian cancer: factors involved in elevation of serum galactosyltransferase.
    Saitoh E; Aoki D; Susumu N; Udagawa Y; Nozawa S
    Int J Oncol; 2003 Aug; 23(2):303-10. PubMed ID: 12851678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Purification and some properties of uridine diphosphate galactose-glycoprotein galactosyltransferase isolated from human parotid saliva].
    Taniguchi T
    Osaka Daigaku Shigaku Zasshi; 1978 Dec; 23(2):195-212. PubMed ID: 118243
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictive value of relative changes in serum total sialic acid level for response to neoadjuvant chemotherapy in patients with locally advanced breast carcinoma.
    Celen O; Yildirim E; Ozen N; Sonmez C
    Neoplasma; 2006; 53(4):347-51. PubMed ID: 16830065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum N-acetyl-beta-glucosaminidase activity in breast cancer.
    Severini G; Aliberti LM
    Cancer Biochem Biophys; 1994 Sep; 14(2):87-92. PubMed ID: 7889495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate-dependent protein-protein interactions in the regulation of lactose synthase.
    Brew K; Powell JT
    Fed Proc; 1976 Jun; 35(8):1892-8. PubMed ID: 817946
    [No Abstract]   [Full Text] [Related]  

  • 11. A new method for detecting beta 1,4-galactosyltransferase activity in sera of cancer patients.
    Taki T; Nishiwaki S; Handa N; Hattori N; Handa S
    Anal Biochem; 1994 May; 219(1):104-8. PubMed ID: 8059935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of interleukin-8 determination in diagnosis of benign and malignant breast tumor].
    Zakrzewska I; Kozłowski L; Wojtukiewicz M
    Pol Merkur Lekarski; 2002 Oct; 13(76):302-4. PubMed ID: 12557436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of UDP-galactose glycoprotein:galactosyltransferase levels in the sera with the clinical status of ovarian cancer patients.
    Chatterjee SK; Bhattacharya M; Barlow JJ
    Cancer Lett; 1978 Nov; 5(5):239-44. PubMed ID: 103615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum tumor markers in skeletal metastasis.
    Tsukushi S; Katagiri H; Kataoka T; Nishida Y; Ishiguro N
    Jpn J Clin Oncol; 2006 Jul; 36(7):439-44. PubMed ID: 16815865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of plasma D-dimer levels and serum VEGF levels in patients with hepatocellular carcinoma.
    Tseng CS; Lo HW; Chen PH; Chuang WL; Juan CC; Ker CG
    Hepatogastroenterology; 2004; 51(59):1454-8. PubMed ID: 15362775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor markers in breast cancer.
    Tondini C; Hayes DF; Kufe DW
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):653-74. PubMed ID: 2691493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosynthesis of lactosylceramide and paragloboside by human lactose synthase A protein.
    Yamato K; Yoshida A
    J Biochem; 1982 Oct; 92(4):1123-7. PubMed ID: 6816790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The expression of NCC-ST-439, a tumor marker, in human breast cancer patients].
    Miyahara E; Toi M; Wada T; Yamada H; Osaki A; Yanagawa E; Toge T
    Gan No Rinsho; 1990 Sep; 36(11):2023-6. PubMed ID: 2232168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
    Sütterlin M; Bussen S; Trott S; Caffier H
    Anticancer Res; 1999; 19(4A):2567-70. PubMed ID: 10470196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum tumor markers in patients with breast cancer.
    Lumachi F; Basso SM
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):921-31. PubMed ID: 15485325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.